- Home
- DHT vs DNLI Comparison
DHT vs DNLI Comparison
Compare DHT & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DHT | DNLI |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 2005 | 2017 |
Fundamental Metrics
Financial Performance| Metric | DHT | DNLI |
|---|---|---|
| Price | $16.70 | $19.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $19.33 | ★ $34.33 |
| AVG Volume (30 Days) | ★ 2.8M | 1.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.85 | N/A |
| Revenue Next Year | N/A | $408.85 |
| P/E Ratio | $12.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.61 | $12.58 |
| 52 Week High | $20.55 | $23.77 |
Technical Indicators
Market Signals| Indicator | DHT | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 47.90 |
| Support Level | $12.59 | $18.27 |
| Resistance Level | $18.80 | $20.55 |
| Average True Range (ATR) | 0.55 | 0.91 |
| MACD | -0.11 | 0.04 |
| Stochastic Oscillator | 27.42 | 47.84 |
Price Performance
Historical ComparisonAbout DHT DHT Holdings Inc.
DHT Holdings Inc is a crude oil tanker company. The company's primary business is operating a fleet of crude oil tankers, with a secondary activity of providing technical management services. Its fleet trades internationally and consists of VLCC crude oil tankers. The group generates revenues from time charter and spot market operations. It operates vessels through its subsidiary management companies in Monaco, Norway, Singapore, and India. The company generates the majority of its revenue from Voyage charter revenues.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.